Verzenios

RSS

abemaciclib

Authorised
This medicine is authorised for use in the European Union.

Overview

Verzenios is a cancer medicine used to treat women with breast cancer that is advanced or has spread to other parts of the body. Verzenios can only be used when the cancer cells have certain types of receptor (called hormone receptors) on their surface (HR-positive) and do not produce abnormally large quantities of another receptor called HER2 (HER2-negative).

It is used together with a hormonal medicine, either an aromatase inhibitor or fulvestrant.

In women who have not yet reached menopause, a medicine called a luteinising hormone-releasing hormone agonist should also be given.

Verzenios contains the active substance abemaciclib.

This EPAR was last updated on 21/01/2019

Authorisation details

Product details
Name
Verzenios
Agency product number
EMEA/H/C/004302
Active substance
abemaciclib
International non-proprietary name (INN) or common name
abemaciclib
Therapeutic area (MeSH)
Breast Neoplasms
Anatomical therapeutic chemical (ATC) code
L01XE50
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Eli Lilly Nederland B.V.
Revision
2
Date of issue of marketing authorisation valid throughout the European Union
26/09/2018
Contact address

Papendorpseweg 83
3528 BJ Utrecht
Netherlands

Product information

26/11/2018 Verzenios - EMEA/H/C/004302 - IAIN/0002/G

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Verzenios is indicated for the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.

Assessment history

How useful was this page?

Add your rating
Average
1 rating
5 ratings